Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (547)

ProteinS (185)

ComplexRdRp (33)

ProteinE (33)

ORF1ab (27)


SARS-CoV-2 Proteins
    displaying 541 - 547 records in total 547
    records per page

    Laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infection MESHDs

    Authors: Yang Yang; Minghui Yang; Chenguang Shen; Fuxiang Wang; Jing Yuan; Jinxiu Li; Mingxia Zhang; Zhaoqin Wang; Li Xing; Jinli Wei; Ling Peng; Gary Wong; Haixia Zheng; Mingfeng Liao; Kai Feng; Jianming Li; Qianting Yang; Juanjuan Zhao; Zheng Zhang; Lei Liu; Yingxia Liu

    doi:10.1101/2020.02.11.20021493 Date: 2020-02-12 Source: medRxiv

    Background: The outbreak of novel coronavirus pneumonia MESHD ( NCP PROTEIN) caused by 2019-nCoV spread rapidly, and elucidation the diagnostic accuracy of different respiratory specimens is crucial for the control and treatment of this diseases. Methods: Respiratory samples including nasal swabs, throat swabs, sputum and bronchoalveolar lavage fluid MESHD ( BALF MESHD) were collected from Guangdong CDC confirmed NCP PROTEIN patients, and viral RNAs were detected using a CFDA approved detection kit. Results were analyzed in combination with sample collection date and clinical information. Finding: Except for BALF MESHD, the sputum possessed the highest positive rate (74.4%~88.9%), followed by nasal swabs (53.6%~73.3%) for both severe and mild cases during the first 14 days after illness onset (d.a.o). For samples collected [≥] 15 d.a.o, sputum and nasal swabs still possessed a high positive rate ranging from 42.9%~61.1%. The positive rate of throat swabs collected [≥] 8 d.a.o was low, especially in samples from mild cases. Viral RNAs could be detected in all the lower respiratory tract of severe cases, but not the mild cases. CT scan of cases 02, 07 and 13 showed typical viral pneumonia MESHD with ground glass opacity, while no viral RNAs were detected in first three or all the upper respiratory samples. Interpretation: Sputum is most accurate for laboratory diagnosis of NCP PROTEIN, followed by nasal swabs. Detection of viral RNAs in BLAF is necessary for diagnosis and monitoring of viruses in severe cases. CT scan could serve as an important make up for the diagnosis of NCP PROTEIN. Funding National Science and Technology Major Project, Sanming Project of Medicine and China Postdoctoral Science Foundation.

    Network-based Drug Repurposing for Human Coronavirus

    Authors: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng

    doi:10.1101/2020.02.03.20020263 Date: 2020-02-05 Source: medRxiv

    Human Coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle east respiratory syndrome coronavirus (MERS-CoV) MESHD, and 2019 novel coronavirus (2019-nCoV), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV has the highest nucleotide sequence identity with SARS-CoV MESHD (79.7%) among the six other known pathogenic HCoVs. Specifically, the envelope and nucleocapsid proteins PROTEIN of 2019-nCoV are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV MESHD. Using network proximity analyses of drug targets and known HCoV-host interactions in the human protein-protein interactome, we computationally identified 135 putative repurposable drugs for the potential prevention and treatment of HCoVs. In addition, we prioritized 16 potential anti-HCoV repurposable drugs (including melatonin, mercaptopurine, and sirolimus) that were further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. Finally, we showcased three potential drug combinations (including sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the Complementary Exposure pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human protein-protein interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations toward future clinical trials for HCoVs.

    Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies

    Authors: Syed Faraz Ahmed; Ahmed A. Quadeer; Matthew R. McKay

    doi:10.1101/2020.02.03.933226 Date: 2020-02-04 Source: bioRxiv

    The beginning of 2020 has seen the emergence of COVID-19 MESHD outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV MESHD, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV MESHD. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV MESHD, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins PROTEIN that map identically to SARS-CoV-2 proteins MESHD. As no mutation has been observed in these identified epitopes among the available SARS-CoV-2 sequences (as of 9 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.

    Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development

    Authors: Arunachalam Ramaiah; Vaithilingaraja Arumugaswami

    doi:10.1101/2020.01.29.925867 Date: 2020-01-30 Source: bioRxiv

    Novel Coronavirus (nCoV) outbreak in the city of Wuhan, China during December 2019, has now spread to various countries across the globe triggering a heightened containment effort. This human pathogen is a member of betacoronavirus genus carrying 30 kilobase of single positive-sense RNA genome. Understanding the evolution, zoonotic transmission, and source of this novel virus would help accelerating containment and prevention efforts. The present study reported detailed analysis of 2019-nCoV genome evolution and potential candidate peptides for vaccine development. This nCoV genotype might have been evolved from a bat-CoV by accumulating non-synonymous mutations, indels, and recombination events. Structural proteins Spike MESHD proteins Spike (S PROTEIN), and Membrane (M) had extensive mutational changes, whereas Envelope (E) and Nucleocapsid (N) proteins PROTEIN were very conserved suggesting differential selection pressures exerted on 2019-nCoV during evolution. Interestingly, 2019-nCoV Spike protein PROTEIN contains a 39 nucleotide sequence insertion relative to SARS-like bat-SL-CoVZC45/2017. Furthermore, we identified eight high binding affinity (HBA) CD4 T-cell epitopes in the S, E, M and N proteins PROTEIN, which can be commonly recognized by HLA-DR alleles of Asia and Asia-Pacific Region MESHD population. These immunodominant epitopes can be incorporated in universal subunit CoV vaccine. Diverse HLA types and variations in the epitope binding affinity may contribute to the wide range of immunopathological outcomes of circulating virus in humans. Our findings emphasize the requirement for continuous surveillance of CoV strains in live animal markets to better understand the viral adaptation to human host and to develop practical solutions to prevent the emergence of novel pathogenic CoV strains.

    Evolution and variation of 2019-novel coronavirus

    Authors: Chenglong Xiong; Lufang Jiang; Yue Chen; Qingwu Jiang

    doi:10.1101/2020.01.30.926477 Date: 2020-01-30 Source: bioRxiv

    BackgroundThe current outbreak caused by novel coronavirus (2019-nCoV) in China has become a worldwide concern. As of 28 January 2020, there were 4631 confirmed cases and 106 deaths, and 11 countries or regions were affected. MethodsWe downloaded the genomes of 2019-nCoVs and similar isolates from the Global Initiative on Sharing Avian Influenza Database (GISAID and nucleotide database of the National Center for Biotechnology Information (NCBI). Lasergene 7.0 and MEGA 6.0 softwares were used to calculate genetic distances of the sequences, to construct phylogenetic trees, and to align amino acid sequences. Bayesian coalescent phylogenetic analysis, implemented in the BEAST software package, was used to calculate the molecular clock related characteristics such as the nucleotide substitution rate and the most recent common ancestor (tMRCA) of 2019-nCoVs. ResultsAn isolate numbered EPI_ISL_403928 showed different phylogenetic trees and genetic distances of the whole length genome, the coding sequences (CDS) of ployprotein (P), spike protein (S PROTEIN), and nucleoprotein (N PROTEIN) from other 2019-nCoVs. There are 22, 4, 2 variations in P, S, and N at the level of amino acid residues. The nucleotide substitution rates from high to low are 1{middle dot}05 x 10-2 (nucleotide substitutions/site/year, with 95% HPD interval being 6.27 x 10-4 to 2.72 x 10-2) for N, 5.34 x 10-3 (5.10 x 10-4, 1.28 x 10-2) for S, 1.69 x 10-3 (3.94 x 10-4, 3.60 x 10-3) for P, 1.65 x 10-3 (4.47 x 10-4, 3.24 x 10-3) for the whole genome, respectively. At this nucleotide substitution rate, the most recent common ancestor (tMRCA) of 2019-nCoVs appeared about 0.253-0.594 year before the epidemic. ConclusionOur analysis suggests that at least two different viral strains of 2019-nCoV are involved in this outbreak that might occur a few months earlier before it was officially reported.

    Transmission dynamics of 2019 novel coronavirus (2019-nCoV)

    Authors: Tao Liu; Jianxiong Hu; Jianpeng Xiao; Guanhao He; Min Kang; Zuhua Rong; Lifeng Lin; Haojie Zhong; Qiong Huang; Aiping Deng; Weilin Zeng; Xiaohua Tan; Siqing Zeng; Zhihua Zhu; Jiansen Li; Dexin Gong; Donghua Wan; Shaowei Chen; Lingchuan Guo; Yan Li; Limei Sun; Wenjia Liang; Tie Song; Jianfeng He; Wenjun Ma

    doi:10.1101/2020.01.25.919787 Date: 2020-01-26 Source: bioRxiv

    RationaleSeveral studies have estimated basic production number of novel coronavirus pneumonia MESHD ( NCP PROTEIN). However, the time-varying transmission dynamics of NCP PROTEIN during the outbreak remain unclear. ObjectivesWe aimed to estimate the basic and time-varying transmission dynamics of NCP PROTEIN across China, and compared them with SARS. MethodsData on NCP PROTEIN cases by February 7, 2020 were collected from epidemiological investigations or official websites. Data on severe acute respiratory syndrome (SARS) cases in Guangdong Province, Beijing and Hong Kong during 2002-2003 were also obtained. We estimated the doubling time, basic reproduction number (R0) and time-varying reproduction number (Rt) of NCP PROTEIN and SARS. Measurements and main resultsAs of February 7, 2020, 34,598 NCP PROTEIN cases were identified in China, and daily confirmed cases decreased after February 4. The doubling time of NCP PROTEIN nationwide was 2.4 days which was shorter than that of SARS in Guangdong (14.3 days), Hong Kong (5.7 days) and Beijing (12.4 days). The R0 of NCP PROTEIN cases nationwide and in Wuhan were 4.5 and 4.4 respectively, which were higher than R0 of SARS in Guangdong (R0=2.3), Hongkong (R0=2.3), and Beijing (R0=2.6). The Rt for NCP PROTEIN continuously decreased especially after January 16 nationwide and in Wuhan. The R0 for secondary NCP PROTEIN cases in Guangdong was 0.6, and the Rt values were less than 1 during the epidemic. ConclusionsNCP may have a higher transmissibility than SARS, and the efforts of containing the outbreak are effective. However, the efforts are needed to persist in for reducing time-varying reproduction number below one. At a Glance CommentaryO_ST_ABSScientific Knowledge on the SubjectC_ST_ABSSince December 29, 2019, pneumonia infection with 2019-nCoV, now named as Novel Coronavirus Pneumonia ( NCP PROTEIN), occurred in Wuhan, Hubei Province, China. The disease has rapidly spread from Wuhan to other areas. As a novel virus, the time-varying transmission dynamics of NCP PROTEIN remain unclear, and it is also important to compare it with SARS. What This Study Adds to the FieldWe compared the transmission dynamics of NCP PROTEIN with SARS, and found that NCP PROTEIN has a higher transmissibility than SARS. Time-varying production number indicates that rigorous control measures taken by governments are effective across China, and persistent efforts are needed to be taken for reducing instantaneous reproduction number below one.

    The 2019-new Coronavirus epidemic: evidence for virus evolution

    Authors: Domenico Benvenuto; Marta Giovanetti; Alessandra Ciccozzi; Silvia Spoto; Silvia Angeletti; Massimo Ciccozzi

    doi:10.1101/2020.01.24.915157 Date: 2020-01-24 Source: bioRxiv

    There is concern about a new coronavirus, the 2019-nCoV, as a global public health threat. In this article, we provide a preliminary evolutionary and molecular epidemiological analysis of this new virus. A phylogenetic tree has been built using the 15 available whole genome sequence of 2019-nCoV and 12 whole genome sequences highly similar sequences available in gene bank (5 from SARS, 2 from MERS and 5 from Bat SARS-like Coronavirus). FUBAR analysis shows that the Nucleocapsid and the Spike Glycoprotein PROTEIN has some sites under positive pressure while homology modelling helped to explain some molecular and structural differences between the viruses. The phylogenetic tree showed that 2019.nCoV significantly clustered with Bat SARS-like Coronavirus sequence isolated in 2015, whereas structural analysis revealed mutation in S and nucleocapsid proteins PROTEIN. From these results, 2019nCoV could be considered a coronavirus distinct from SARS virus, probably transmitted from bats or another host where mutations conferred upon it the ability to infect humans.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.